Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc. Collagen meniscus implant (CMI) (Menaflex; Ivy Sports Medicine LLC) for meniscal repair. Lansdale: HAYES, Inc. Healthcare Technology Brief Publication. 2017 Authors' conclusions Meniscal loss or dysfunction causes abnormal wear on articular cartilage, promoting degeneration and osteoarthritis of the knee joint. Because of the limited vascularity of cartilaginous tissue, injuries to the menisci may not heal properly.
Description of Technology: The collagen meniscal implant (CMI) (formerly marketed as Menaflex) is an implant derived from bovine collagen used to treat acute or chronic advanced meniscal loss or damage with the intent of relieving symptoms and preventing joint degeneration. The CMI is a flexible, sickle-shaped disc that mimics the shape of the native meniscus and is attached arthroscopically to native tissue with suture. The porous, collagen-glycosaminoglycan matrix of the CMI is meant to serve as a temporary template to support migration of the host's cells to the meniscal deficiency, restoring meniscal volume and function.
Patient Population: Meniscal replacement with CMI is indicated for patients with advanced loss of or damage to meniscal tissue that cannot be repaired and in whom an intact rim of meniscal tissue is present. The amount of damaged tissue must be > 25% of the total meniscus area and should extend at least into the red-white zone.
Clinical Alternatives: Partial meniscectomy is the conventional treatment for meniscal tear or subtotal loss when repair is not possible. While CMI is intended for patients with at least 25% meniscus remaining, human allograft transplantation is typically reserved for patients with total or near-total meniscal loss. Indexing Status Subject indexing assigned by CRD MeSH Arthroplasty, Replacement, Knee; Collagen; Humans; Menisci, Tibial; Meniscus; Sports Medicine Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: hayesinfo@hayesinc.com AccessionNumber 32017000179 Date abstract record published 04/04/2017 |
